Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02089386 · ClinicalTrials.gov registry record · Early Phase 1

Tamoxifen to Treat Barrett's Metaplasia

A Early Phase 1 study, sponsored by Washington University School of Medicine.

Terminated
Registry status
Early Phase 1
Development phase
7
Enrollment target

NCT02089386 is a Early Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02089386, a Early Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.

TERMINATED
Registry status
Early Phase 1
Development phase
7 participants
Enrollment target

Study Summary

Treat Barrett's esophagus (BE) patients with tamoxifen to Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy and histology as well as changes in SOX2 and CDX2.

Interventions

  • DRUG Tamoxifen
  • PROCEDURE Endoscopy

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2014-07-09
Est. Completion 2016-06-21
Phase Early Phase 1

What the Registry Record Tells You About NCT02089386

The ClinicalTrials.gov registry entry for NCT02089386 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.

NCT02089386 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02089386 about?

NCT02089386 is a clinical study titled "Tamoxifen to Treat Barrett's Metaplasia". Treat Barrett's esophagus (BE) patients with tamoxifen to Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy and histology as well as changes in SOX2 and CDX2.

What is the current status of trial NCT02089386?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2014-07-09. Estimated completion is 2016-06-21.

What interventions are being tested in trial NCT02089386?

The interventions under investigation include: Tamoxifen (DRUG), Endoscopy (PROCEDURE).

Who is sponsoring clinical trial NCT02089386?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.